|
**Overview**: Fibromyalgia Panel**Introduction**: The Fibromyalgia Panel is a diagnostic tool designed to screen for fibromyalgia using serum samples. In India, fibromyalgia affects ~2-8 percent of adults (higher in women), characterized by widespread pain, fatigue, sleep disturbance, and tender points, often overlapping with depression or arthritis. High burden from underdiagnosis in rural/low-SES women, limited rheumatology access, delayed multidisciplinary management leading to chronic disability and poor quality of life. Per rheumatology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for CRP and ESR over 1-2 days with high sensitivity for ruling out inflammation, valuable as part of exclusionary workup (normal inflammatory markers support fibromyalgia). This diagnostic falls under chronic pain screening and targets patients with diffuse pain and fatigue, addressing supportive detection to guide symptom management (exercise, CBT, duloxetine). With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise exclusion of organic disease and improving functional outcomes. Its serum-based approach ensures reliable inflammation assessment.**Other Names**: Fibromyalgia Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Inflammatory marker exclusion standard; in India, used in pain clinics.**Purpose**: The test screens for 2 parameters including CRP to guide fibromyalgia assessment, rule out inflammation, inform symptom management.**Test Parameters**: 1. CRP, 2. ESR.**Pretest Condition**: No fasting required; patients should report widespread pain, fatigue.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on pain sites, sleep, mood, prior rheumatology workup.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of misdiagnosis including untreated pain, benefits of exclusionary screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infection can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Normal CRP/ESR supports fibromyalgia diagnosis, necessitating specialist input. Elevated may require further investigation.**Specialist Consultation**: Rheumatologists should be consulted for management.**Additional Supporting Tests**: Thyroid function, vitamin D for confirmation.**Test Limitations**: Nonspecific markers; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, Fibromyalgia Studies India 2023. |
